ELTROMBOPAG

ELTROMBOPAG: Eltrombopag is a medication used for the treatment of low platelet counts (thrombocytopenia) in patients with chronic immune thrombocytopenia (ITP), severe aplastic anemia, or chronic hepatitis C infection.

The mechanism of action of eltrombopag involves increasing the production and maturation of platelets in the bone marrow. It is a thrombopoietin receptor agonist, which means it binds to and stimulates the receptors for thrombopoietin, a growth factor that regulates platelet production. By activating these receptors, eltrombopag promotes the differentiation and proliferation of megakaryocytes (platelet precursor cells), leading to increased platelet production.

The dose of eltrombopag depends on the specific condition being treated. For adults with chronic ITP, the usual starting dose is 50 mg once daily, which may be adjusted every 2 weeks based on platelet count response. The recommended maximum dose for chronic ITP is 75 mg once daily. For patients with severe aplastic anemia, the starting dose is 150 mg once daily, which may be increased every 2 weeks up to a maximum of 300 mg once daily. The dose for chronic hepatitis C-related thrombocytopenia ranges from 25 mg to 100 mg once daily, depending on the patient’s baseline platelet count and the treatment regimen for hepatitis C.

Common side effects of eltrombopag include headache, nausea, diarrhea, abdominal pain, muscle pain, dizziness, and rash. It can also cause an increase in liver enzyme levels, which should be monitored regularly. Some patients may develop blood clots or new or worsening cataracts with long-term use of eltrombopag, so caution should be exercised in those with a history of clotting disorders or eye problems. Additionally, it is important to note that eltrombopag can interact with certain medications, so it is crucial to inform the healthcare provider about all other medications being taken.